Search results for " Liver resection"

showing 8 items of 8 documents

Totally laparoscopic liver resections for primary and metastatic cancer in the elderly: safety, feasibility and short-term outcomes.

2012

Standard oncologic liver resections performed on elderly patients (≥70 years old) have been shown to be safe and effective. The aim of this study was to analyze operative and oncologic short-term outcomes of totally laparoscopic liver resections (TLLR) performed on elderly patients for malignancies. We performed a retrospective statistical analysis of prospectively recorded data of TLLR performed from October 2008 to February 2012 by a single hepato-pancreato-biliary (HPB) surgeon. Patients were divided into two groups according to age (<70 vs. ≥70 years old) and perioperative outcomes were compared. A total of 60 TLLR for malignancies were identified of which 25 patients (42 %) were aged ≥…

AdultMalemedicine.medical_specialtyBlood transfusionCarcinoma HepatocellularCritical Caremedicine.medical_treatmentOperative TimePostoperative ComplicationsmedicineHepatectomyHumansLiver neoplasmProspective StudiesProspective cohort studyAgedRetrospective StudiesAged 80 and overbusiness.industryMortality rateLiver NeoplasmsRetrospective cohort studyPerioperativeLength of StayMiddle AgedLAPAROSCOPIC LIVER RESECTIONS METASTATIC CANCERSurgeryTreatment OutcomeSurgeryFemaleLaparoscopyHepatectomyNeoplasm Recurrence LocalbusinessAbdominal surgerySurgical endoscopy
researchProduct

Fully robotic left hepatectomy for malignant tumor: technique and initial results

2018

Robotic liver surgery has been considered as a unique opportunity to overcome the traditional limitations of laparoscopy; thus, it can potentially extend the indications of minimally invasive liver surgery. From April 2015 to May 2017, 35 patients underwent fully robotic left hepatectomy. The mean operative time was 315 min (200-445 min) and the mean estimated blood loss was 245 ml (125-628 ml). Pringle maneuver was required in six cases. Cancer was the indication for surgery in all patients (14 liver metastases, 18 hepatocellular carcinomas and 3 cholangiocarcinomas). There were one to four lesions in a patient and the mean lesion size was 39.2 mm (15-85 mm). The average length of hospital…

Adultmedicine.medical_specialtyCarcinoma Hepatocellularmedicine.medical_treatmentOperative TimeBlood Loss Surgical030230 surgeryCholangiocarcinomaLesion03 medical and health sciences0302 clinical medicineRobotic Surgical ProceduresBlood lossMinimally invasive surgerymedicineHepatectomyHumansRobotic left hepatectomyLaparoscopyAgedLiver resectionmedicine.diagnostic_testbusiness.industryMortality rateLiver NeoplasmsMargins of ExcisionCancerPerioperativeLength of StayMiddle Agedmedicine.diseaseRobotic liver resectionSurgerySettore MED/18 - Chirurgia GeneraleTreatment OutcomeLiver030220 oncology & carcinogenesisOperative timeFemaleSurgeryHepatectomymedicine.symptombusinessUpdates in Surgery
researchProduct

ERAS Protocol for Perioperative Care of Patients Treated with Laparoscopic Nonanatomic Liver Resection for Hepatocellular Carcinoma: The ISMETT Exper…

2020

Background: Liver resection (LR) remains the best therapeutic option for patients with early-stage hepatocellular carcinoma (HCC) with preserved hepatic function and who are not eligible for liver transplantation. After its inception, the enhanced recovery after surgery (ERAS) protocol was widely used for treating patients with liver cancer, although there are still no clear indications for improving upon it in both open and laparoscopic surgery. Objective: This study aims to describe our institute's experience in the application of the ERAS protocol in a cohort of HCC patients, and to explore possible factors that could have an impact on postoperative outcomes. Materials and Methods: We re…

Laparoscopic surgeryLiver CirrhosisMalemedicine.medical_specialtyCirrhosisCarcinoma Hepatocellularmedicine.medical_treatmentLiver transplantation03 medical and health sciences0302 clinical medicinePostoperative ComplicationsmedicineHepatectomyHumansERASPostoperative PeriodAgedRetrospective StudiesAnalgesicsbusiness.industryNutritional SupportLiver NeoplasmsRetrospective cohort studyPerioperativehepatocellular carcinomalaparoscopic liver resectionLength of StayMiddle Agedmedicine.diseaseSurgery030220 oncology & carcinogenesisHepatocellular carcinomaoutcome030211 gastroenterology & hepatologySurgeryFemaleLaparoscopyHepatectomybusinessLiver cancerEnhanced Recovery After Surgery
researchProduct

Multisciplinary management of patients with liver metastasis from colorectal cancer

2016

Abstract: Colorectal cancer (CRC) is one of the leading causes of cancer-related death. Surgery, radiotherapy and chemotherapy have been till now the main therapeutic strategies for disease control and improvement of the overall survival. Twenty-five per cent (25%) of CRC patients have clinically detectable liver metastases at the initial diagnosis and approximately 50% develop liver metastases during their disease course. Twenty-thirty per cent (20%-30%) are CRC patients with metastases confined to the liver. Some years ago various studies showed a curative potential for liver metastases resection. For this reason some authors proposed the conversion of unresectable liver metastases to res…

Liver metastase0301 basic medicinemedicine.medical_specialtyChemotherapy; Colorectal cancer; Liver metastases; Liver resection; Multidisciplinary team; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therapy; Disease Management; Hepatectomy; Humans; Liver Neoplasms; Receptor; Epidermal Growth Factor; GastroenterologyColorectal cancermedicine.medical_treatmentAngiogenesis InhibitorsColorectal NeoplasmReviewChemotherapy; Colorectal cancer; Liver metastases; Liver resection; Multidisciplinary team; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modality Therapy; Disease Management; Hepatectomy; Humans; Liver Neoplasms; Receptor Epidermal Growth Factor; GastroenterologyMetastasis03 medical and health sciencesLiver metastases0302 clinical medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineCombined Modality TherapyChemotherapyHepatectomyHumansDisease management (health)ChemotherapyAntineoplastic Combined Chemotherapy ProtocolLiver resectionEpidermal Growth Factorbusiness.industryGeneral surgeryHepatobiliary diseaseLiver NeoplasmsGastroenterologyDisease ManagementGeneral MedicineMultidisciplinary teammedicine.diseaseColorectal cancerCombined Modality TherapyRadiation therapyErbB Receptors030104 developmental biologyLiver Neoplasm030220 oncology & carcinogenesisReceptor Epidermal Growth FactorHuman medicineHepatectomybusinessColorectal NeoplasmsAngiogenesis InhibitorHumanReceptor
researchProduct

Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages: a multicentre s…

2015

Background &amp; Aims The role of hepatic resection for hepatocellular carcinoma (HCC) in different Barcelona Clinic Liver Cancer (BCLC) stages is controversial. We aimed at measuring the survival benefit of resection vs. non-surgical-therapies in each BCLC stage. Methods Using the ITA.LI.CA database, we identified 2090 BCLC A, B, and C HCC patients observed between 2000 and 2012: 550 underwent resection, 1046 loco-regional therapy (LRT), and 494 best supportive care (BSC). A multivariate log-logistic model was chosen to predict median survival (MS) after resection vs. MS after LRT or BSC. The results were expressed as net survival benefit of resection: (MS resection - MS LRT)/MS BSC. Resul…

Malemedicine.medical_specialtyCirrhosisCarcinoma HepatocellularLoco-regional therapieHepatocellular carcinomaSettore MED/12 - GASTROENTEROLOGIAHepatitis C virusKaplan-Meier Estimatemedicine.disease_causeGastroenterologyCohort StudiesLiver diseaseInterquartile rangeInternal medicinemedicineHumansBest supportive care; Cirrhosis; Hepatocellular carcinoma; Liver resection; Loco-regional therapies; Survival benefit; Aged; Carcinoma Hepatocellular; Cohort Studies; Female; Humans; Italy; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Prognosis; Treatment Outcome; Medicine (all); HepatologyBEST SUPPORTING CAREAgedNeoplasm StagingCirrhosiHepatologyPerformance statusLiver resectionbusiness.industryMedicine (all)CIRRHOISISCarcinomaLiver NeoplasmsHepatocellularMiddle Agedmedicine.diseasePrognosisBCLC StageTreatment OutcomeCirrhosisItalySurvival benefitHepatocellular carcinomaMultivariate AnalysisFemaleLoco-regional therapiesLiver cancerbusinessBest supportive careJournal of hepatology
researchProduct

Impact of margin status on long-term results of liver resection for hepatocellular carcinoma: single-center time-to-recurrence analysis

2020

Occult metastasis from the initial tumor and a de novo second primary hepatocellular carcinoma (HCC) were recognized as the main causes for the onset of early and late HCC recurrence, after liver resection (LR). This study aims to compare the time to recurrence after LR for HCC in which a margin ≤ 1 mm or &gt; 1 mm was achieved. A single-center retrospective study involving 256 patients was conducted from June 2005 to June 2019. HCC patients resected with a radical surgical approach were investigated and stratified into groups A (resection margins ≤ 1 mm) and B (&gt; 1 mm), as measured on final pathologic assessment. Kaplan–Meier estimators were used to estimate the probability of recurrenc…

medicine.medical_specialtyCarcinoma HepatocellularTime FactorsHepatocellular carcinomaHepatocellular carcinoma; Liver resection; Liver transplantation; Margin status; Outcome030230 surgerySingle CenterGastroenterologyGroup BMetastasis03 medical and health sciences0302 clinical medicineInternal medicineHepatocellular carcinoma Liver resection Liver transplantation Margin status Outcome Carcinoma Hepatocellular Liver Neoplasms Neoplasm Recurrence Local Neoplasms Second Primary Time Factors Hepatectomy Margins of ExcisionEpidemiologyHepatectomyHumansMedicineMargin statusPathologicalOutcomeLiver transplantationLiver resectionbusiness.industryProportional hazards modelLiver NeoplasmsMargins of ExcisionNeoplasms Second PrimaryRetrospective cohort studymedicine.diseaseSurgery030220 oncology & carcinogenesisHepatocellular carcinomaSurgeryNeoplasm Recurrence Localbusiness
researchProduct

Monofocal hepatocellular carcinoma: How much does size matter?

2020

Background &amp; Aims: According to the Barcelona Clinic Liver Cancer (BCLC) staging system, monofocal hepatocellular carcinoma (HCC) is classified as early (BCLC A) irrespective of its size, even though controversies still exist regarding staging and treatment of large tumours. We aimed at evaluating the appropriate staging and treatment for large (&gt;5 cm) monofocal (HCC). Methods: From the Italian Liver Cancer database, we selected 924 patients with small early monofocal HCC (2-5 cm; SEM-HCC), 163 patients with larger tumours (&gt;5 cm; LEM-HCC) and 1048 intermediate stage patients (BCLC B). Results: LEM-HCC patients had a worse overall survival (OS) than SEM-HCC (31.0 vs 49.0 months; P…

medicine.medical_specialtyMultivariate analysisCarcinoma HepatocellularIndependent predictorGastroenterologyResection03 medical and health sciences0302 clinical medicineInternal medicinemedicineOverall survivalHepatectomyHumansStaging systemNeoplasm StagingRetrospective StudiesSettore MED/12 - GastroenterologiaHepatologytreatmentbusiness.industrySettore MED/09 - MEDICINA INTERNALiver Neoplasmsbclc staging systemmonofocal hepatocellular carcinomamedicine.diseasedigestive system diseasesSurvival benefitItaly030220 oncology & carcinogenesisHepatocellular carcinomabclc staging system; liver resection; monofocal hepatocellular carcinoma; prognosis; treatmentliver resection030211 gastroenterology & hepatologyprognosisbusinessLiver cancerprognosi
researchProduct

Liver Resection for Intrahepatic Cholangiocarcinoma—Single-Center Experience with 286 Patients Undergoing Surgical Exploration over a Thirteen Year P…

2021

Background: Intrahepatic cholangiocarcinoma (iCCA) accounts for about 10% of primary liver cancer. Surgery is the only potentially curative treatment. We report on our current series of 229 consecutive hepatic resections for iCCA, which is one of the largest Western single-center series published so far. Methods: Between January 2008 to December 2020, a total of 286 patients underwent 307 surgical explorations for intended liver resection of iCCA at our department. Data were analyzed with regard to (1) preoperative treatment of tumor, (2) operative details, (3) perioperative morbidity and mortality, (4) histopathology, (5) outcome measured by tumor recurrence, treatment of recurrence and su…

medicine.medical_specialtyProportional hazards modelbusiness.industrymedicine.medical_treatmentRGeneral MedicinePerioperativeSingle Centersurvivalrepeated liver resectionArticleSurgeryintrahepatic cholangiocarcinomaliver resectionmedicineMedicineT-stageHistopathologyHepatectomyStage (cooking)businesscholangiocarcinomaIntrahepatic CholangiocarcinomaJournal of Clinical Medicine
researchProduct